Furthermore, CBF‐AML patients in the UAMOCS2 group demonstrated a lower relapse rate compared to those in UAMOCS3 (22.2% vs. 60%, P = 0.04). The gene discussed is CEBPZ; the disease is acute myeloid leukemia.